Case Report
BibTex RIS Cite

Sodium Taurocolate Cotransporting Polypeptide Mutation Associated Transaminase Elevation

Year 2024, Volume: 18 Issue: 4, 253 - 255, 22.07.2024
https://doi.org/10.12956/tchd.1416503

Abstract

Familial hypercholanemia-2 is a condition caused by mutations in the human solute carrier family 10 member 1
(SLC10A1) gene, which results in the inability to transport conjugated bile salts from plasma to hepatocytes. This is due
to the sodium taurocholate cotransport polypeptide encoded by the gene being affected. Although the gene was first
described in 1994, there is limited knowledge on the clinical features of the disease. In the few reported cases, both clinical
and laboratory findings have varied. We reported a twelve-year-old girl was diagnosed with familial hypercholanemia-2
through a whole gene exome sequencing study. She was brought in with asymptomatic hypertransaminasemia, and
after comprehensive studies on etiology failed to detect the cause, genetic testing was done. The patient had no
clinically abnormal findings but had hypercholanemia (bile acid level 81.9 μmol/L) (fasting < 10 μmol/L, postprandial <
15 μmol/L) and hypertransaminasemia in laboratory examinations.
It is believed that the disease can present with a wide range of phenotypes, and laboratory findings may differ between
patients depending on the underlying genetic mutation or mechanisms that have not yet been identified. Therefore, it is
recommended to expand diagnostic genetic examinations in patients with hypertransaminasemia whose cause cannot
be determined

References

  • Deng M, Mao M, Guo L, Chen FP, Wen WR, Song YZ. Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency. Exp Ther Med 2016;12:3294-300.
  • 2. Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011;201:205-59.
  • 3. Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology 2015;61:260-7.
  • 4. Tan HJ, Deng M, Qiu JW, Wu JF, Song YZ. Monozygotic Twins Suffering From Sodium Taurocholate Cotransporting Polypeptide Deficiency: A Case Report. Front Pediatr 2018;6:354.
  • 5. Dong C, Zhang BP, Wang H, Xu H, Zhang C, Cai ZS, et al. Clinical and histopathologic features of sodium taurocholate cotransporting polypeptide deficiency in pediatric patients. Medicine (Baltimore) 2019;98:e17305.
  • 6. Zou TT, Zhu Y, Wan CM, Liao Q. Clinical features of sodiumtaurocholate cotransporting polypeptide deficiency in pediatric patients: case series and literature review.Transl Pediatr 2021;10:1045-54.
  • 7. Lin H, Qiu JW, Rauf YM, Lin GZ, Liu R, Deng LJ, et al. Sodium Taurocholate Cotransporting Polypeptide (NTCP) Deficiency Hidden Behind Citrin Deficiency in Early Infancy: A Report of Three Cases. Front Genet 2019;10:1108.

Sodyum Taurokolat Taşıyan Polipeptit Mutasyonuna Bağlı Transaminaz Yüksekliği

Year 2024, Volume: 18 Issue: 4, 253 - 255, 22.07.2024
https://doi.org/10.12956/tchd.1416503

Abstract

Ailesel hiperkolanemi-2, SLC10A1 genindeki mutasyonların neden olduğu, konjuge safra tuzlarının plazmadan
hepatositlere taşınmasındaki bozukluk ile sonuçlanan bir durumdur. Bunun nedeni, etkilenen gen tarafından kodlanan sodyum taurokolat kotransport polipeptididir. Gen ilk olarak 1994 yılında tanımlanmış olmasına rağmen hastalığın klinik özelliklerine ilişkin bilgiler sınırlıdır. Bildirilen birkaç vakada da hem klinik hem de laboratuvar bulguları farklılık göstermiştir. Bu yazımızda; tüm ekzon dizi analizi çalışmasıyla; ailesel hiperkolanemi-2 tanısı alan on iki yaşında bir kız hastayı sunuyoruz. Asemptomatik hipertransaminazemi nedeniyle getirilen hastaya, etiyolojiye yönelik kapsamlı çalışmalar sonucunda nedenin belirlenememesi üzerine genetik temelli tanı testleri yapıldı. Klinik olarak asemptomatik olan hastanın, laboratuvar incelemelerinde hiperkolanemi (safra asidi düzeyi 81.9 μmol/L) (açlık < 10 μmol/L, tokluk < 15 μmol/L) ve hipertransaminazemi mevcuttu. Hastalığın çok çeşitli fenotiplerle ortaya çıkabileceği ve altta yatan genetik mutasyon veya henüz tanımlanamayan mekanizmalara bağlı olarak laboratuvar bulgularının hastalar arasında farklılık gösterebileceği düşünülmektedir. Bu nedenle nedeni belirlenemeyen hipertransaminazemili hastalarda tanısal genetik incelemelerin yaygınlaştırılması önerilmektedir.

References

  • Deng M, Mao M, Guo L, Chen FP, Wen WR, Song YZ. Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency. Exp Ther Med 2016;12:3294-300.
  • 2. Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. Handb Exp Pharmacol 2011;201:205-59.
  • 3. Vaz FM, Paulusma CC, Huidekoper H, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology 2015;61:260-7.
  • 4. Tan HJ, Deng M, Qiu JW, Wu JF, Song YZ. Monozygotic Twins Suffering From Sodium Taurocholate Cotransporting Polypeptide Deficiency: A Case Report. Front Pediatr 2018;6:354.
  • 5. Dong C, Zhang BP, Wang H, Xu H, Zhang C, Cai ZS, et al. Clinical and histopathologic features of sodium taurocholate cotransporting polypeptide deficiency in pediatric patients. Medicine (Baltimore) 2019;98:e17305.
  • 6. Zou TT, Zhu Y, Wan CM, Liao Q. Clinical features of sodiumtaurocholate cotransporting polypeptide deficiency in pediatric patients: case series and literature review.Transl Pediatr 2021;10:1045-54.
  • 7. Lin H, Qiu JW, Rauf YM, Lin GZ, Liu R, Deng LJ, et al. Sodium Taurocholate Cotransporting Polypeptide (NTCP) Deficiency Hidden Behind Citrin Deficiency in Early Infancy: A Report of Three Cases. Front Genet 2019;10:1108.
There are 7 citations in total.

Details

Primary Language English
Subjects Clinical Sciences (Other)
Journal Section CASE REPORTS
Authors

Zeynep Begüm Erensoy Karagül 0009-0008-5638-8928

Coskun Firat Özkeçeci 0000-0002-3954-6428

Melike Arslan 0000-0002-0107-4699

Edibe Gözde Başaran 0000-0003-3165-3234

Yasin Maruf Ergen 0000-0002-3689-6852

Necati Balam 0000-0001-8665-5611

Early Pub Date May 13, 2024
Publication Date July 22, 2024
Submission Date January 9, 2024
Acceptance Date March 4, 2024
Published in Issue Year 2024 Volume: 18 Issue: 4

Cite

Vancouver Erensoy Karagül ZB, Özkeçeci CF, Arslan M, Başaran EG, Ergen YM, Balam N. Sodium Taurocolate Cotransporting Polypeptide Mutation Associated Transaminase Elevation. Türkiye Çocuk Hast Derg. 2024;18(4):253-5.


The publication language of Turkish Journal of Pediatric Disease is English.


Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.


The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.